Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines

Expected Outcome: This action supports the follow-up to the July 2023 Communication on EU Missions assessment[1]. Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes: Public procurers, possibly in cooperation with private ones, in the area of cancer-centred healthcare stimulate the competitive development of market-ready, affordable, innovative solutions. The chosen solutions take into consideration the needs of cancer patients living with and beyond cancer through research that supports end-user engagement using participative research models. Procurers create opportunities for European health, technology and medical devices, industrial actors (including start-ups, spin-offs, spin-outs, scale-ups, SMEs) to bring to the market affordable innovations that are cost-efficient, safe and have demonstrated improved health outcomes for cancer patients living with and beyond cancer. Procurers facilitate the commercialisation of innovative solutions for and with cancer patients by their successful suppliers through providing them with first customer references for the validation and first pilot deployment. Policymakers, healthcare providers and professionals, cancer patients and their carers – each in their respective areas – exchange and adopt good practices and the best treatment, technology and medical device solutions that the market can deliver through participative research.…